Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

Nutrition & Food Research 59 (7), 13641372
This product is only intended for laboratory research use and thus the buyer assumes all responsibility for the safe handling and use of any materials purchased
By targeting key areas related to energy and mood, these injections help you feel your best every day
Anecdotal 'evidence' can suggest that parenteral B12 may be over-used in some patients, so whilst I share your worries, then if the GP is set on trying this out, make sure you are monitored carefully because it's your health that's at stake